{{{PM me to join GLOVE Private Discussion Room}}}

I am reproducing the CNA article to my blog.

CNA is quoting from an official, who declined to be identified by name.

Glove is the vaccine to your wealth in this pandemic.

MACQUARIE raised Top Glove's Target Price to RM30.40

TA raised TOPGLOV target price to RM31.66

Kenanga raised TOPGLOV target price to RM32

Top Glove eyes expansion through organic growth and M&A

America is running short on GLOVES. Again. - Washington Post

Cold Eye Commented on GLOVE in his new book

 CIMB: No concern on lower ASPs and oversupply on GLOVE. Toppick is TOPGLOV (RM25) and SUPERMX (RM9.80)

TOP GLOVE is having trouble keeping up with demand even at full capacity

TAN SRI DR LIM WEE CHAI spend 25 million to buyback TOPGLOV share again. He bought at RM16 and RM17

https://www.channelnewsasia.com/news/world/us-covid-19-vaccine-program-to-start-manufacturing-by-late-summer--says-us-official-12929270

US COVID-19 vaccine program to start manufacturing by late summer, says US official

REUTERS: Drugmakers partnered with the US government are on track to begin actively manufacturing a vaccine for COVID-19 by the end of the summer, a senior administration official said on Monday (Jul 13).

"If you say exactly when will literally the vaccine materials be in production and manufacturing, it is probably four to six weeks away, but we will be actively manufacturing by the end of summer," the official, who declined to be identified by name, said.

He added that the administration is already working with companies to equip and outfit manufacturing facilities and acquire raw materials.

The Trump administration has helped finance the development of four COVID-19 vaccines so far though its Operation Warp Speed Program, which aims to produce 300 million vaccine doses by the end of 2021.

The US government has given grants ranging from several hundred million dollars to over US$1 billion to Johnson & Johnson, Moderna Inc, AstraZeneca Plc and Novovax Inc.

It also signed a US$450 million contract earlier this month with Regeneron Pharmaceuticals Inc to help it supply therapies for patients who are sick with the virus.

Clinical trials for therapeutics can produce results in a matter of weeks, making it possible to produce hundreds of thousands of doses by fall, the senior administration official said.

"While we think is fair to say that vaccine progress is occurring at warp speed pace, faster than any vaccines have been developed in history, therapeutics are even faster," the official said.

The "slate is not closed" for additional funding agreements and the administration plans to announce more in the future, the official said.

The novel coronavirus has infected more than 3 million people in the United States and killed more than 130,000.